GEM联合CBP与NVB联合DDP治疗老年NSCLC对比研究

目的：对比观察吉西他滨（Gemcitabine，GEM）联合卡铂（CBP）及长春瑞滨（NVB）联合顺铂（DDP）方案在晚期老年非小细胞肺癌临床疗效及毒性反应。方法：40例晚期老年（大于60岁）肺非小细胞肺癌，被随机分为两组为吉西他滨＋卡铂组20例，长春瑞滨＋顺铂组20例。吉西他滨1000mg／m^2，d1、d8，卡铂300mg／m^2，第1天，每3周为1周期；长春瑞堂皇mg／m^2d1、d8，顺铂的剂量80mg／m^2，分第1、3两天用，每3周为1周期。结果：吉西他滨组有效率（CR＋PR）为40％，长春瑞滨组有效率（CR＋PR）为35％，有效率两组间差异无显著性（P〉0．05）。中位生存期（MST）、疾病缓解时间（DPT）、一年生存率两组间均无显著性差异（P〉0．05）。但吉西他滨组血小板下降及静脉炎的发生率显著低于长春瑞滨组。结论：吉西他滨联合卡铂与长春瑞滨联合顺铂对晚期老年非小细胞肺癌的近期临床效相近，中位生存期、疾病缓解时间、一年生存率均相似，但GEM＋CBP毒性反应低于NVB＋DDP，GC方案可作为治疗晚期老年非小细胞肺癌的一种安全、有效的化疗方案。

Comparative study of gemcitabine plus CBP and navelbine plus DDP regimen in the treatment of old patients with age NSCLC

Objective: To evaluate and compare the effects and safety of GC(GEZ+CBP) regimen and NP(NVB=DDP) regimen for old age patients with advancde non-small cell lung cancer(NSCLC).Methods: The 40 cases of old age patients with advancde NSCLC were randomly divided into GC regimen group and NP regimen group,twenty cases of each group respectively received GEM+CBP regimen and NVB+DDP regimen.The patients received GEM 1000mg/m2 on 1st and 8th day and CBP 300 mg/m2 on 1st day.NVB 25mg/m2 on 1st and 8th day and DDP 80mg/m2 with 1st and 3th day.Course was repeated every 3 weeks.Results: The response rate(CR+PR) were 40% and 35% respectively for GEM and NVB groups.There was no significant difference existed between the two groups(P>0.05),and also the MST,DPT and one-year survival rate(P>0.05).But the rates of thrombocytopenia and phlebitis in GEM group were significantly lower than NVB group.Conclusions: The short-time clinical efficacy,MST,DPT and one-year survival rate of GEM+CBP regimen were similar to those of NVB+DDP regimen,but the toxicity of GEM+CBP regimen were lower than those of NVB+DDP regimen.The GC regimen is a safe and effective regimen for old age advancde NSCLC.